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Association of common variants 
in atrial natriuretic peptide genes, 
plasma concentrations,  
and blood pressure
The reason blood pressure varies among individuals is somewhat 
unclear. Although blood pressure is substantially heritable, studies of 
the pathways involved in its control, such as the renin–angiotensin–
aldosterone and the adrenergic systems, have failed to show that 
genetic variations contribute to interindividual differences in blood 
pressure. On the other hand, it was recently shown that rare muta-
tions in renal salt-handling genes contribute to blood pressure vari-
ation. The family of vasodilatory and natriuretic hormones known 
as natriuretic peptides is secreted in response to increased wall 
stress. Among their many known functions, they induce vasodila-
tion, increase glomerular filtration, and inhibit tubular sodium rea-
bsorption. Hence, it has long been suspected that they are involved 
in blood pressure regulation. In mice, knockout of one copy of the 
atrial natriuretic peptide (ANP) gene, but not the B-type natriuretic 
peptide (BNP) gene, is associated with salt-sensitive hypertension. 
Overexpression of ANP through gene therapy in hypertensive mice 
lowers systolic blood pressure. To date, however, clinical studies have 
failed to establish a causal link between the natriuretic peptide axis 
and blood pressure variation in humans. The natriuretic peptide pre-
cursor A (NPPA) and natriuretic peptide precursor B (NPPB) genes 
lie in tandem 9.7 kb apart on chromosome 1. In a recent study, New-
ton-Cheh et al. examined the association between common variants 
at the NPPA–NPPB locus and circulating concentrations of the natri-
uretic peptides and blood pressure. They genotyped single-nucle-
otide polymorphisms at the NPPA–NPPB locus in 14,743 individuals 
of European ancestry. They then identified associations of plasma 
ANP with rs5068, rs198358, and rs632793 (all with P between 2 × 
10–10 and 8 × 10–70) and of plasma BNP with rs5068, rs198358, and 
rs632793 (all with P between 3 × 10–12 and 2 × 10–68). A graded rela-
tionship of increasing ANP and BNP concentrations with increasing 
copies of the alleles of rs5068, rs198358, and rs632793 was observed 
in both hypertensive and nonhypertensive groups (Figure). In 29,717 
individuals, the alleles of rs5068 and rs198358 that showed associa-
tion with increased circulating natriuretic peptide concentrations 
were also associated with lower systolic and diastolic blood pressure, 
as well as reduced odds of hypertension. Thus, the study uses the 
natural experiment of the random mendelian assortment of alleles to 
show that common genetic variants at the NPPA–NPPB locus associ-
ated with circulating natriuretic peptide concentrations contribute to 
interindividual variation in blood pressure and hypertension. Thera-
peutic agents that chronically activate the natriuretic peptide system 
are under active development. The finding that genetic variation 
of natriuretic peptide concentrations is associated with blood pres-
sure and hypertension suggests that these agents might prove useful 
for the treatment of hypertension. (Nat Genet 2009; 41: 348–353; 
doi:10.1038/ng.328)
Qais Al-Awqati
Intensive versus conventional 
glucose control  
in critically ill patients
Acute kidney injury is common in the critically ill population and 
portends a significant increase in mortality. Various methods of 
renal replacement therapies fail to demonstrate a strategy that 
improves outcomes. Therefore, alternative therapies are needed to 
improve outcomes in these critically ill patients. Several large dedi-
cated studies have examined the effect of intensive control of blood 
glucose on outcomes. One study of two trials found that intensive 
control reduced renal injury and failure from 7.6% to 4.5%.1
A new trial randomized 6,104 intensive care unit (ICU) patients 
to undergo either intensive glucose control, with a target blood 
glucose range of 81–108 mg/dl (4.5–6.0 mmol/l), or conventional 
glucose control, with a target of 180 mg/dl or less (10.0 mmol/l or 
less). All-cause death within 90 days was the primary end point. 
In the intensive group, 27.5% of subjects died, while 24.9% died in 
the conventional group (P = 0.02). The effect was not significantly 
different in surgical and medical patients. While the intensive-
therapy group experienced more hypoglycemia (6.8% versus 0.5%, 
P<0.001), no differences were noted in ICU, hospital, or mechani-
cal-ventilation days. The requirement for renal replacement therapy 
was seen in 15.4% as compared with 14.5% of the intensive- and 
conventional-therapy groups, respectively (P = 0.34).
Like previous trials, this one demonstrated that intensive glucose 
therapy does not affect the need for renal replacement therapy. 
However, this trial showed that intensive glucose control increased 
the risk of mortality, whereas the prior study showed a benefit.1 
The renal community now needs to carefully assess how these con-
tradictory findings can be reconciled. (N Engl J Med 2009; 360: 
1283–1297; doi:10.1056/NEJMoa0810625)
Lynda Szczech
1J Am Soc Nephrol 2008; 19: 571–578.
Association of common variants in NPPA and NPPB with circulating 
natriuretic peptides and blood pressure. ANP, atrial natriuretic peptide; 
BNP, B-type natruiretic peptide; HTN, hypertension.
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Glomerular type 1 angiotensin 
receptors increase kidney injury
Angiotensin II, acting through type 1 angiotensin (AT1) recep-
tors, contributes to the pathophysiology of diverse disorders, from 
progressive renal disease to cardiac hypertrophy to atherosclero-
sis. In addition, recent studies have suggested that AT1 receptors 
may contribute to disease pathogenesis through direct effects 
on cellular immune responses and inflammation. For example, 
angiotensin II triggers T-lymphocyte proliferation through a cal-
cineurin-dependent pathway during the alloimmune response. 
Furthermore, blockade of the AT1 receptor or targeted deletion 
of the dominant murine AT1 receptor isoform, AT1A, prolongs 
allograft survival in rodent models. In contrast, actions of AT1 
receptors may have protective effects in other disorders. In autoim-
mune glomerulonephritis, previous studies suggest that blockade 
of the renin–angiotensin system has beneficial effects. MRL/MpJ-
Faslpr/lpr (lpr) mice develop florid autoimmune disease resembling 
human systemic lupus erythematosus, including autoantibodies, 
arthritis, and proliferative glomerulonephritis. Treatment of lpr 
mice with angiotensin-converting enzyme inhibitors or AT1 recep-
tor blockers reduces glomerular injury and albuminuria. To clarify 
the role of the AT1 receptors in the development of autoimmune 
disease, Crowley et al. generated an lpr mouse line deficient in the 
major murine AT1 receptor, AT1A, and characterized its clinical 
features. Surprisingly, AT1A deficiency was not protective against 
disease; it substantially accelerated mortality, proteinuria, and kid-
ney pathology. Increased disease severity was not a direct effect of 
immune cells, since transplantation of AT1A-deficient bone mar-
row to lpr mice did not affect survival. Moreover, autoimmune 
injury in extrarenal tissues, including skin, heart, and joints, was 
unaffected by AT1A deficiency. In murine systems, a second type 1 
angiotensin receptor isoform exists, AT1B, and its expression is 
especially prominent in podocytes. Interestingly, AT1A-deficient 
lpr mice had enhanced renin expression in their kidneys and 
showed evidence of exaggerated AT1B receptor activation, includ-
ing substantially increased podocyte injury (Figure) and expres-
sion of inflammatory mediators. Losartan, which blocks all type 1 
angiotensin receptors, was administered and reduced markers of 
kidney disease, including proteinuria, glomerular pathology, and 
cytokine mRNA expression. Since AT1A-deficient lpr mice had 
low blood pressure, these findings suggest that activation of AT1 
receptors in the glomerulus is sufficient to increase renal injury and 
inflammation in the absence of hypertension. (J Clin Invest 2009; 
119: 943−953, doi:10.1172/JCI34862) 
Juan Oliver
Urinary L-type fatty acid−binding  
protein reflects renal 
tubulointerstitial injury
A new study by Tanaka et al. examined the role of L-type fatty 
acid−binding protein (L-FABP) in renal tubulointerstitial injury 
using a mouse adenine-induced renal injury model. C57BL/6 mice 
fed excess dietary adenine for 6 weeks showed a gradual increase in 
levels of blood urea nitrogen (BUN). They also showed severe tubu-
lointerstitial pathological findings, such as fibrosis and macrophage 
infiltration without glomerular damage (Figure). These conditions 
were attenuated by treatment with either allopurinol or Y-700, a 
new xanthine dehydroxygenase inhibitor. Because renal expression 
of L-FABP is defective in C57BL/6 mice, human-L-FABP trans-
genic mice were fed an adenine-containing diet. Transgenic mice 
showed lower BUN levels and lower levels of pathological injury 
compared with wild-type mice. On the other hand, urinary levels 
and renal expression of L-FABP in the adenine group were sig-
nificantly increased and were attenuated by treatment with either 
allopurinol or Y-700. Urinary L-FABP was positively correlated 
with BUN levels and pathological damage in the tubulointersti-
tium. No increases in urinary protein, albumin, or N-acetyl-β-d-
glucosaminidase levels were found for 6 weeks in any group. In 
conclusion, the authors demonstrated that urinary L-FABP levels 
can be used to monitor both dynamics and drug responses in a 
mouse adenine-induced tubulointerstitial injury model. (Am J 
Pathol 2009; 174: 1203–1211; doi:10.2353/ajpath.2009.080511)
Marc De Broe
Enhanced podocyte injury in kidneys from lpr knockout (AT1A-deficient) 
mice. Staining for desmin, a marker of podocyte injury, in lpr (a) and lpr 
knockout mice (b).
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Renal pathological injury induced by excess dietary adenine.
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